BioXcel Therapeutics, Inc. (BTAI)

0.18 -74.83% (-0.54)

Over 1Y: -95.6%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

2 4
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Operating Cash Flow: -20.2M Q3 '21 — Free Cash Flow: -20.2M Q3 '21 — Net Income: -26.8M Q4 '21 — Operating Cash Flow: -19.9M Q4 '21 — Free Cash Flow: -19.9M Q4 '21 — Net Income: -26.1M Q1 '22 — Operating Cash Flow: -32.4M Q1 '22 — Free Cash Flow: -32.5M Q1 '22 — Net Income: -31.5M Q2 '22 — Operating Cash Flow: -33.1M Q2 '22 — Free Cash Flow: -33.1M Q2 '22 — Net Income: -37.7M Q3 '22 — Revenue: 137K Q3 '22 — Operating Cash Flow: -31.2M Q3 '22 — Free Cash Flow: -31.2M Q3 '22 — Net Income: -41.8M Q4 '22 — Revenue: 238K Q4 '22 — Operating Cash Flow: -38.6M Q4 '22 — Free Cash Flow: -38.6M Q4 '22 — Net Income: -54.8M Q1 '23 — Revenue: 206K Q1 '23 — Operating Cash Flow: -52.4M Q1 '23 — Net Income: -52.8M Q2 '23 — Revenue: 457K Q2 '23 — Operating Cash Flow: -38.2M Q2 '23 — Net Income: -53.5M Q3 '23 — Revenue: 341K Q3 '23 — Operating Cash Flow: -37.6M Q3 '23 — Free Cash Flow: -37.6M Q3 '23 — Net Income: -50.5M Q4 '23 — Revenue: 376K Q4 '23 — Operating Cash Flow: -26.9M Q4 '23 — Free Cash Flow: -26.9M Q4 '23 — Net Income: -22.3M Q1 '24 — Revenue: 582K Q1 '24 — Operating Cash Flow: -17.7M Q1 '24 — Net Income: -26.8M Q2 '24 — Revenue: 1.1M Q2 '24 — Operating Cash Flow: -23.2M Q2 '24 — Net Income: -8.3M Q3 '24 — Revenue: 214K Q3 '24 — Operating Cash Flow: -16.3M Q3 '24 — Free Cash Flow: -16.3M Q3 '24 — Net Income: -13.7M Q4 '24 — Revenue: 366K Q4 '24 — Operating Cash Flow: -14.8M Q4 '24 — Free Cash Flow: -14.8M Q4 '24 — Net Income: -10.9M Q1 '25 — Revenue: 168K Q1 '25 — Operating Cash Flow: -12M Q1 '25 — Free Cash Flow: -12M Q1 '25 — Net Income: -7.3M Q2 '25 — Revenue: 120K Q2 '25 — Operating Cash Flow: -12.6M Q2 '25 — Free Cash Flow: -12.6M Q2 '25 — Net Income: -19.2M Q3 '25 — Revenue: 98K Q3 '25 — Operating Cash Flow: -18.8M Q3 '25 — Free Cash Flow: -18.8M Q3 '25 — Net Income: -30.9M Q4 '25 — Revenue: 256K Q4 '25 — Operating Cash Flow: -14.2M Q4 '25 — Free Cash Flow: -14.2M Q4 '25 — Net Income: -12.5M Q1 '26 — Revenue: 206K Q1 '26 — Operating Cash Flow: -11.8M Q1 '26 — Free Cash Flow: -11.8M Q1 '26 — Net Income: -12.7M Q2 '26 — Revenue: 182K Q2 '26 — Operating Cash Flow: -6.1M Q2 '26 — Free Cash Flow: -6.1M Q2 '26 — Net Income: -14.7M -45M -30M -15M 0 15M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.7
SBC / sales 245.8%
ROIC -44.0%
Accruals -69.3%
Gross margin 53.1%
Asset turnover 0.026×
ROA -246.1%
Capex / sales —
EBITDA margin —
FCF margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROCE —
ROE —

2 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.2
ND/EBITDA —
Current ratio 0.21×
Cash / Debt 0.061×
F-score 3.0 pts
Quick ratio 0.21×
Cash runway —
Debt / Eq —
Debt payback —
Equity / Assets —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.2
Sales/sh Y/Y -82.3%
Sales Q/Q +51.7%
Shares change +382.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.